AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the present application:

Listing of Claims:

1. (**Previously Presented**) A compound represented by the formula:



(I)

a pharmacologically acceptable salt thereof or hydrates thereof, wherein in the formula, R^1 represents the formula:



wherein:

(R^3)s are the same as or different from each other and each represents hydrogen atom, a halogen atom, hydroxyl group, a C_{1-6} alkyl group, a C_{3-8} cycloalkyl group, a C_{1-6} alkoxy group, a C_{1-6} alkoxyalkoxy group, a halogeno C_{1-6} alkyl group, a hydroxy C_{1-6} alkyl group, a cyano C_{1-6} alkyl group, an amino C_{1-6} alkyl group, a halogeno C_{1-6} alkoxy group, a hydroxy C_{1-6} alkoxy group, a cyano C_{1-6} alkoxy group, a lower acyl group, nitro group, an optionally substituted amino group, an optionally substituted carbamoyl group, mercapto group or a C_{1-6} thioalkoxy group;

R^5 represents a halogen atom (provided that fluorine is excluded), hydroxy group, a C_{1-6} alkyl group, a C_{1-6} alkoxy group, cyano group, a halogeno C_{1-6} alkyl group, a cyano C_{1-6} alkyl group, an amino C_{1-6} alkyl group, nitro group, an azido group, an optionally substituted amino group, an optionally substituted carbamoyl group, an optionally substituted carboxyl group, mercapto group or a C_{1-6} thioalkoxy group;

m is 0 or an integer from 1 to 6; and

n is an integer from 1 to 4; and

R^2 represents a C_{3-8} cycloalkylmethyl, a 2,2-(alkylenedioxy)ethyl or a group represented by the formula:



wherein:

the ring A represents a benzene ring or a heterocyclic ring;

(R^6)s are the same as or different from each other and each represents hydrogen, a halogen atom, hydroxyl group, nitrile group, a C_{1-6} alkyl group, a C_{3-8} cycloalkyl group, a C_{1-6} alkoxy group, a C_{1-6} alkoxyalkoxy group, an aryloxy group, an aralkyloxy group, a halogeno C_{1-6} alkyl group, a hydroxy C_{1-6} alkyl group, a cyano C_{1-6} alkyl group, a halogeno C_{1-6} alkoxy group, a hydroxy C_{1-6} alkoxy group, a cyano C_{1-6} alkoxy group, a lower acyl group, nitro group, an optionally substituted amino group, an optionally substituted amide group, mercapto group or a C_{1-6} thioalkoxy group, and

two of the R^6 may together form an aliphatic ring, an aromatic ring, a heterocyclic ring or an alkylenedioxy ring; and

q is 0 or an integer from 1 to 5.

2. (**Previously Presented**) The compound according to Claim 1, a pharmacologically acceptable salt thereof or hydrates thereof, wherein R^1 is represented by the formula:



in which R^{3a} and R^{3b} are the same as or different from each other and each represents a C_{1-6} alkoxy group;

R^5 represents a halogen atom (provided that fluorine is excluded), hydroxy group, a C_{1-6} alkyl group, a C_{1-6} alkoxy group, cyano group, a halogeno C_{1-6} alkyl group, a cyano C_{1-6} alkyl group, an amino C_{1-6} alkyl group, nitro group, an azido group, an optionally substituted amino group, an optionally substituted carbamoyl group, an optionally substituted carboxyl group, mercapto group or a C_{1-6} thioalkoxy group; and

m is 0 or an integer from 1 to 6.

3. (**Original**) The compound according to Claim 2, a pharmacologically acceptable salt thereof or hydrates thereof, wherein R^{3a} and R^{3b} are methoxy groups.

4. (**Previously Presented**) A compound represented by the formula:



(I)

a pharmacologically acceptable salt thereof or hydrates thereof,

wherein in the formula, R^1 represents the formula:



wherein:

(R^3)s are the same as or different from each other and each represents hydrogen atom, a halogen atom, hydroxyl group, a C_{1-6} alkyl group, a C_{3-8} cycloalkyl group, a C_{1-6} alkoxy group, a C_{1-6} alkoxyalkoxy group, a halogeno C_{1-6} alkyl group, a hydroxy C_{1-6} alkyl group, a cyano C_{1-6} alkyl group, an amino C_{1-6} alkyl group, a halogeno C_{1-6} alkoxy group, a hydroxy C_{1-6} alkoxy group, a cyano C_{1-6} alkoxy group, a lower acyl group, nitro group, an optionally substituted amino group, an optionally substituted carbamoyl group, mercapto group or a C_{1-6} thioalkoxy group;

R^5 is chlorine or bromine;

m is 0 or an integer from 1 to 6; and

n is an integer from 1 to 4; and

R^2 represents a C_{3-8} cycloalkylmethyl, a 2,2-(alkylenedioxy)ethyl or a group represented by the formula:



wherein:

the ring A represents a benzene ring or a heterocyclic ring;

(R^6)s are the same as or different from each other and each represents hydrogen, a halogen atom, hydroxyl group, nitrile group, a C_{1-6} alkyl group, a C_{3-8} cycloalkyl group, a C_{1-6} alkoxy group, a C_{1-6} alkoxyalkoxy group, an aryloxy group, an aralkyloxy group, a halogeno C_{1-6} alkyl group, a hydroxy C_{1-6} alkyl group, a cyano C_{1-6} alkyl group, a halogeno C_{1-6} alkoxy group, a hydroxy C_{1-6} alkoxy group, a cyano C_{1-6} alkoxy group, a lower acyl group, nitro group, an optionally substituted amino group, an optionally substituted amide group, mercapto group or a C_{1-6} thioalkoxy group, and

two of the R^6 may together form an aliphatic ring, an aromatic ring, a heterocyclic ring or an alkylenedioxy ring; and

q is 0 or an integer from 1 to 5.

5. (**Original**) The compound according to Claim 1, a pharmacologically acceptable salt thereof or hydrates thereof, wherein m is 1.

6. (**Previously Presented**) The compound according to Claim 1, a pharmacologically acceptable salt thereof or hydrates thereof, wherein R^2 is a group represented by the formula:



wherein:

the ring A represents a benzene ring or a heterocyclic ring;

(R^6)s are the same as or different from each other and each represents hydrogen, a halogen atom, hydroxyl group, nitrile group, a C_{1-6} alkyl group, a C_{3-8} cycloalkyl group, a C_{1-6} alkoxy group, a C_{1-6} alkoxyalkoxy group, an aryloxy group, an aralkyloxy group, a halogeno C_{1-6} alkyl group, a hydroxy C_{1-6} alkyl group, a cyano C_{1-6} alkyl group, a halogeno C_{1-6} alkoxy group, a hydroxy C_{1-6} alkoxy group, a cyano C_{1-6} alkoxy group, a lower acyl group, nitro group, an optionally substituted amino group, an optionally substituted amide group, mercapto group or a C_{1-6} thioalkoxy group, and

two of the R^6 may together form an aliphatic ring, an aromatic ring, a heterocyclic ring or an alkylenedioxy ring; and

q is 0 or an integer from 1 to 5.

7. (**Original**) The compound according to Claim 6, a pharmacologically acceptable salt thereof or hydrates thereof, wherein the ring A is a benzene ring.

8. (**Previously Presented**) A compound represented by the formula:

 (I)

a pharmacologically acceptable salt thereof or hydrates thereof, wherein in the formula, R^1 represents the formula:



wherein:

(R^3)s are the same as or different from each other and each represents hydrogen atom, a halogen atom, hydroxyl group, a C_{1-6} alkyl group, a C_{3-8} cycloalkyl group, a C_{1-6} alkoxy group, a C_{1-6} alkoxyalkoxy group, a halogeno C_{1-6} alkyl group, a hydroxy C_{1-6} alkyl group, a cyano C_{1-6} alkyl group, an amino C_{1-6} alkyl group, a halogeno C_{1-6} alkoxy group, a hydroxy C_{1-6} alkoxy group, a cyano C_{1-6} alkoxy group, a lower acyl group, nitro group, an optionally substituted amino group, an optionally substituted carbamoyl group, mercapto group or a C_{1-6} thioalkoxy group;

R^5 represents a halogen atom (provided that fluorine is excluded), hydroxy group, a C_{1-6} alkyl group, a C_{1-6} alkoxy group, cyano group, a halogeno C_{1-6} alkyl group, a hydroxy C_{1-6} alkyl group, a cyano C_{1-6} alkyl group, an amino C_{1-6} alkyl group, nitro group, an azido group, an optionally substituted amino group, an optionally substituted carbamoyl group, an optionally substituted carboxyl group, mercapto group or a C_{1-6} thioalkoxy group;

m is 0 or an integer from 1 to 6; and

n is an integer from 1 to 4; and

R^2 represents a C_{3-8} cycloalkylmethyl, a 2,2-(alkylenedioxy)ethyl or a group represented by the formula:



wherein the ring A is a pyridine ring;

(R^6)s are the same as or different from each other and each represents hydrogen, a halogen atom, hydroxyl group, nitrile group, a C_{1-6} alkyl group, a C_{3-8} cycloalkyl group, a C_{1-6} alkoxy group, a C_{1-6} alkoxyalkoxy group, an aryloxy group, an aralkyloxy group, a halogeno C_{1-6} alkyl group, a hydroxy C_{1-6} alkyl group, a cyano C_{1-6} alkyl group, a halogeno C_{1-6} alkoxy group, a hydroxy C_{1-6} alkoxy group, a cyano C_{1-6} alkoxy group, a lower acyl group, nitro group, an optionally substituted amino group, an optionally substituted amide group, mercapto group or a C_{1-6} thioalkoxy group, and two of the R^6 may together form an aliphatic ring, an aromatic ring, a heterocyclic ring or an alkylenedioxy ring; and

q is 0 or an integer from 1 to 5.

9. (**Original**) The compound according to Claim 6, a pharmacologically acceptable salt thereof or hydrates thereof, wherein q is an integer of 1 or 2.

10. (**Previously Presented**) The compound according to Claim 1, a pharmacologically acceptable salt thereof or hydrates thereof, which is selected from the group consisting of:

1-benzyl-4-[(5,6-dimethoxy-2-chloro-1-indanon)-1-yl]methylpiperidine,

1-benzyl-4-[(5,6-dimethoxy-2-bromo-1-indanon)-2-yl]methylpiperidine,

1-benzyl-4-[(5,6-dimethoxy-2-iodo-1-indanon)-2-yl]methylpiperidine,

1-benzyl-4-[(5,6-dimethoxy-2-hydroxy-1-indanon)-2-yl]methylpiperidine,

1-benzyl-4-[(5,6-dimethoxy-2-methyl-1-indanon)-2-yl]methylpiperidine,

1-benzyl-4-[(5,6-dimethoxy-2-ethyl-1-indanon)-2-yl]methylpiperidine,

1-benzyl-4-[(5,6-dimethoxy-2-azido-1-indanon)-2-yl]methylpiperidine,

1-benzyl-4-[(5,6-dimethoxy-2-amino-1-indanon)-2-yl]methylpiperidine,

1-benzyl-4-[(5,6-dimethoxy-2-methylamino-1-indanon)-2-yl]methylpiperidine,

1-benzyl-4-[(5,6-dimethoxy-2-dimethylamino-1-indanon)-2-yl]methylpiperidine, and

1-benzyl-4-[(5,6-dimethoxy-2-acetamide-1-indanon)-2-yl]methylpiperidine.

11-21. **(Canceled)**

22. (**Previously Presented**) A method of treating Alzheimer-type senile dementia, said method comprising administering a pharmacologically effective amount of the compound according to Claim 1, a pharmacologically acceptable salt thereof or hydrates thereof to a patient in need thereof.

23. (**Previously Presented**) A pharmaceutical composition comprising the compound according to Claim 1, a pharmacologically acceptable salt thereof or hydrates thereof; and

a pharmacologically acceptable carrier.

24. (**Previously Presented**) The compound according to Claim 1, the pharmacologically acceptable salt thereof or hydrates thereof, wherein R^5 in the formula represents a halogen atom (provided that fluorine is excluded), hydroxy group, a C_{1-6} alkyl group, a C_{1-6} alkoxy group, cyano group, a halogeno C_{1-6} alkyl group, a cyano C_{1-6} alkyl group, an amino C_{1-6} alkyl group, nitro group, an azido group, an optionally substituted amino group, an optionally substituted carbamoyl group, mercapto group or a C_{1-6} thioalkoxy group.

25. (**New**) A method of treating cerebrovascular dementia, said method comprising administering a pharmacologically effective amount of the compound according to Claim 1, a pharmacologically acceptable salt thereof or hydrates thereof to a patient in need thereof.